Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. (CMMB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CMMB · as of Jun 8, 2026
Key Statistics
Explore Chemomab Therapeutics Ltd. Data
cmmb stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 4 · Buy rate: 100.0%
Competitors & Peers
cmmb competitorsCMMB
BIVI
CANF
CERO
ELAB
GLMDStock Performance
Full HistoryAbout Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental d…
what is chemomab therapeutics ltd. · cmmb stock overview · chemomab therapeutics ltd. company profile · who is chemomab therapeutics ltd. ceo · cmmb NASDAQ · chemomab therapeutics ltd. headquarters · chemomab therapeutics ltd. business segments
About Stock Overview & Key Data
Chemomab Therapeutics Ltd. (CMMB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 12, 2019. As of the latest trading session, CMMB stock price is $1.81, with a market capitalization of $11.1M. The stock has returned -65.72% over the past 12 months and +9.68% year-to-date.
According to 4 Wall Street analysts, the consensus rating for Chemomab Therapeutics Ltd. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Chemomab Therapeutics Ltd. reported revenue of — and net income of -$9.0M. For detailed data — including Chemomab Therapeutics Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Chemomab Therapeutics Ltd. (CMMB) stock price is $1.81. The stock is traded on NASDAQ under the ticker symbol CMMB. The 52-week range is $1.35 – $5.48.